Drug maintenance of a second tumor necrosis factor alpha inhibitor in spondyloarthritis patients: A real-life multicenter study

Krajewski, Faustine; Andras, Lucia; Pereira-Gillion, Céline; Goupille, Philippe; Salliot, Carine

doi:10.1016/j.jbspin.2019.07.003

Cited by 9 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Median retention length of 48 months for 1st line TNFi was concordant with the results in a Korean report 37 . Mean retention length of second-line TNFi was 23 months, which is higher than previously reported duration 38 but concordant with other reports 39 . Other studies did not find such comparable influence of the line of prescription 40 .…”

Section: Discussionsupporting

confidence: 92%

Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network

Larid,

Baudens,

Tiemdjo-Djimaffo

et al. 2024

Sci Rep

View full text Add to dashboard Cite

The objectives of our study were to assess retention rate, safety, and predictive factors for retention of subcutaneous (SC) TNF inhibitors (TNFi) (adalimumab (ADA), etanercept (ETN), golimumab (GOL), and certolizumab pegol (CZP)) in axial spondyloarthritis (axSpA) depending on the line of treatment in real-life conditions. A multicentre retrospective observational study was conducted including 552 patients fulfilling the ASAS criteria for axSpA followed in the RIC-France register who began SC-TNFi between 01/01/13 and 08/31/2018 for a total of 824 prescriptions. Taking all lines of treatment into account, GOL had a significantly higher retention rate compared with ADA, ETN, and CZP with a mean retention length of 59 months. As first-line bDMARDs, GOL had a significantly higher retention rate compared with ADA and ETN. ETN had the best retention rate when prescribed as at least 3rd bDMARD. Taking all lines of treatment into account, female sex, peripheral disease, BASDAI at initiation, and line of treatment were predictive factors for treatment cessation. Primary inefficiency was the most frequent reason for treatment cessation. In conclusion, GOL showed the highest retention rate in axSpA. Male sex, absence of peripheral disease, and early line of prescription were associated with better SC-TNFi retention in axSpA.

show abstract

Section: Discussionsupporting

confidence: 92%

Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network

Larid,

Baudens,

Tiemdjo-Djimaffo

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Our study analyzed real practice data and found out that one third of patients with axSpA (23.2%) and pSpA (27.5%) switched to second TNFα inhibitor and only a small number of them switched to the third anti TNFα drug during a follow-up period of 9 years. These results are in accordance with French registries where switching rate for the first anti TNF alpha drug was of 32% in patients with spondyloarthropathy [13,14]. In the Norwegian-NOR-DMARD registry only 14.9% of AS patients switched the first anti TNF alpha drug during in a period of 9 years [15].…”

Section: Discussionsupporting

confidence: 89%

Persistence on anti-TNF therapy - data from Serbian National Spondyloarthritis Registry

Cvetković¹,

Zivanovic-Radnic

Vojinović

et al. 2023

Srp Arh Celok Lek

View full text Add to dashboard Cite

Introduction/Objective. The Aim of our study was to retrospectively analyze data about efficacy and persistence on different anti-TNF? treatment in spondyloarthritis (SpA). Methods. We retrospectively analyzed SpA patients whose data were entered into the Serbian national SpA registry. All patients were divided in two groups: non-switcher (patients who were treated with one anti-TNF?) and switcher group (who has switched from first to second and third anti-TNF?). Disease activity was measured by the Ankylosing Spondylitis Disease Score and the Bath Ankylosing Spondylitis Disease Activity Index and functional status was measured by the Bath Ankylosing Spondylitis Functional Index. Results. We identified 290 SpA patients-250 patients with axial SpA(axSpA) and 40 patients with peripheral SpA(pSpA). Among 250 patients with axSpA, 192(76.8%) did not change first anti-TNF?, while 58(23.2%) switched to the second and 14/250(5.6%) switched to the third anti-TNF?. Among 40 patients with pSpA, 29(72.5%) did not change first anti-TNF? while 11(27.5%) switched to the second and 3/40(7.5%) switched to the third anti-TNF?. Survival on the first anti-TNF? was 35.16?28.5 months (switchers29.41?21.89 vs non-switchers 36.89 ? 30.04). ?t the moment of this cross-section 37(19.3%) patients still had very high disease activity, while only 75(39%) patients had inactive disease. Conclusions. In real-life clinical practice in our country, as well as in others, there is reluctance to anti-TNF? switch in SpA patients. Administrative limitations and national reimbursement policy could be one of the main reasons limiting treat to target implementation in SpA patients. Additionally, specific drug efficacy on extra-articular manifestations is often the reason for choosing the first line medication or switching to the next one.

show abstract

“…Retention of the second TNFi was shorter than of the first TNFi. In a French study with 244 patients (101 under the first TNFi and 143 on their second TNFi), the drug survival for the first and second TNFi was 22 and 15 months, respectively (p < 0.01), regardless of the individual drug [16]. Concerning ASDAS outcomes, as observed in our study, in a Swiss study, ASDAS-ESR inactive disease state was reached by 4% of patients after previous primary failure against the 22% after secondary failure [2].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?

et al. 2020

View full text Add to dashboard Cite

Background: To investigate whether the reason to discontinue the first TNF inhibitor (TNFi) affects the response to the second TNFi in axial spondyloarthritis (axSpA). Methods: Patients with axSpA from the Rheumatic Diseases Portuguese Register (ReumaPt), who discontinued their first TNFi and started the second TNFi between June 2008 and May 2018, were included. Response was assessed by the Ankylosing Spondylitis Disease Activity Score (ASDAS) clinically important improvement (ASDAS-CII), major important improvement (ASDAS-MI), low disease activity (ASDAS-LDA), and inactive disease (ASDAS-ID). The reason for discontinuation of the first TNFi was defined, according to ASDAS-CII as primary failure (no response ≤ 6 months), secondary failure (response ≤ 6 months but lost thereafter), adverse events, and others. The association between the reason for discontinuation of the first TNFi and response to the second TNFi over time was assessed in multivariable generalized equation (GEE) models. Results: In total, 193 patients were included. The reason for discontinuation of the first TNFi did not influence the response to the second TNFi, according to the ASDAS-CII. However, a difference was found with more stringent outcomes, e.g., there was a higher likelihood to achieve ASDAS-ID with the second TNFi for patients discontinuing the first TNFi due to secondary failure (OR 7.3 [95%CI 1.9; 27.7]), adverse events (OR 9.1 [2.5; 33.3]), or other reasons (OR 7.7 [1.6; 37.9]) compared to primary failure. Conclusion: Patients with axSpA with secondary failure to their first TNFi, compared to those with primary failure, have a better response to the second TNFi according to stringent outcomes.

show abstract

Drug maintenance of a second tumor necrosis factor alpha inhibitor in spondyloarthritis patients: A real-life multicenter study

Cited by 9 publications

References 28 publications

Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network

Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network

Persistence on anti-TNF therapy - data from Serbian National Spondyloarthritis Registry

Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?

Contact Info

Product

Resources

About